ImpediMed Changes to Board of Directors

BRISBANE, Australia and CARLSBAD, Calif., Aug. 8, 2016 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced several changes to its Board of Directors.

Dr. Michael Panaccio, a long-standing director, will retire from the Board of Directors, effective August 8, 2016.

In addition, David Adams will stand down from his position as non-executive Director and member of the Nomination and Audit and Risk Management Committees, to take on an executive role with ImpediMed as Senior Vice President of Ventures, Licensing and Corporate Development.

The company is also pleased to announce that Gary Goetzke will join the ImpediMed Board as a non-executive Director, effective August 8, 2016.

Goetzke has spent 15 years in senior management positions at three medical device companies where he lead efforts in pursuing global coverage and payment policy for a variety of medical device therapies in the areas of cardiology, neurology, urology, pelvic health, wound care, orthopedics, ENT and sleep.

Dr. Cherrell Hirst, Chair of ImpediMed, said the Board and executive appointments bring another dimension of U.S. medical device and financial experience to ImpediMed.

“As ImpediMed extends its commercial presence in the U.S. and pursues new opportunities for its technology, we continue to evolve and add very high caliber talent to the Board and management teams. On behalf of the Board, I would like to thank Michael for his excellent contribution to ImpediMed over many years, and I am very pleased to welcome Gary, who brings a wealth of experience in the medical device industry with considerable experience in U.S. reimbursement.

“I also congratulate David on his appointment to the executive team, and thank him for his valuable contribution to the Board over the past almost three years. In this new role, we will be able to make even better use of David’s skills and experience as we continue on the journey of building a successful global organization.”

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif., and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphedema of the arm and leg in women and the leg in men.

For additional information, visit www.impedimed.com.